Open Access

Efficacy and safety of bevacizumab and platinum‑based chemotherapy as neoadjuvant regimen for stage‑IIIA non‑squamous non‑small cell lung cancer: A retrospective study

  • Authors:
    • Dexiong Jiang
    • Yao Rao
    • Chunxi Zhang
    • Dan Wang
    • Xu Jiang
    • Huachuan Wang
  • View Affiliations

  • Published online on: June 13, 2024     https://doi.org/10.3892/ol.2024.14508
  • Article Number: 375
  • Copyright: © Jiang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Bevacizumab plus platinum‑based chemotherapy provides modest benefits in non‑squamous non‑small cell lung cancer (NSCLC), while its application as a neoadjuvant regimen has yet to be validated. The present study aimed to assess the efficacy of neoadjuvant bevacizumab plus platinum‑based chemotherapy in patients with stage‑IIIA non‑squamous NSCLC. Data from 110 patients with stage‑IIIA non‑squamous NSCLC with negative driver genes, who received neoadjuvant bevacizumab plus platinum‑based chemotherapy (n=50) or neoadjuvant platinum‑based chemotherapy alone (n=60), and tumor resection, were retrospectively reviewed in the current study. In addition, the data on pathological response, disease‑free survival (DFS), overall survival (OS) and adverse events were obtained. The results demonstrated that neoadjuvant bevacizumab plus chemotherapy did not significantly increase the pathological complete response (pCR) rate in comparison with neoadjuvant chemotherapy alone (18.0 vs. 8.3%; P=0.130). However, neoadjuvant bevacizumab plus chemotherapy significantly increased the rates of DFS (P=0.007) and OS (P=0.049) compared with neoadjuvant chemotherapy alone. Adjustments were then performed using multivariate logistic or Cox regression analyses, which demonstrated that neoadjuvant bevacizumab plus chemotherapy in comparison with neoadjuvant chemotherapy alone only significantly independently prolonged DFS [hazard ratio (HR)=0.251; P=0.042], but did not significantly affect pCR (odds ratio=2.897; P=0.117) or OS (HR=0.297; P=0.158). Furthermore, no significant differences were demonstrated between the number of adverse events in patients receiving neoadjuvant bevacizumab plus chemotherapy in comparison with those receiving neoadjuvant chemotherapy alone (all P>0.05). In conclusion, neoadjuvant bevacizumab plus platinum‑based chemotherapy was only associated with a significant improvement in the rate of DFS, but showed limited efficacy in improving pCR and OS rates in comparison with neoadjuvant chemotherapy alone in patients with stage‑IIIA non‑squamous NSCLC. Therefore, a larger sample size and randomized controlled studies are needed for further validation of the findings of the present study.
View Figures
View References

Related Articles

Journal Cover

August-2024
Volume 28 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Jiang D, Rao Y, Zhang C, Wang D, Jiang X and Wang H: Efficacy and safety of bevacizumab and platinum‑based chemotherapy as neoadjuvant regimen for stage‑IIIA non‑squamous non‑small cell lung cancer: A retrospective study. Oncol Lett 28: 375, 2024
APA
Jiang, D., Rao, Y., Zhang, C., Wang, D., Jiang, X., & Wang, H. (2024). Efficacy and safety of bevacizumab and platinum‑based chemotherapy as neoadjuvant regimen for stage‑IIIA non‑squamous non‑small cell lung cancer: A retrospective study. Oncology Letters, 28, 375. https://doi.org/10.3892/ol.2024.14508
MLA
Jiang, D., Rao, Y., Zhang, C., Wang, D., Jiang, X., Wang, H."Efficacy and safety of bevacizumab and platinum‑based chemotherapy as neoadjuvant regimen for stage‑IIIA non‑squamous non‑small cell lung cancer: A retrospective study". Oncology Letters 28.2 (2024): 375.
Chicago
Jiang, D., Rao, Y., Zhang, C., Wang, D., Jiang, X., Wang, H."Efficacy and safety of bevacizumab and platinum‑based chemotherapy as neoadjuvant regimen for stage‑IIIA non‑squamous non‑small cell lung cancer: A retrospective study". Oncology Letters 28, no. 2 (2024): 375. https://doi.org/10.3892/ol.2024.14508